Showing results (1-10 of 195) with videos related to
Sort By:
Pageof 20
Biochimica Et Biophysica Acta|October 25, 2011
MEK5/ERK5 pathway: the first fifteen yearsBarbara A Drew, Matthew E Burow, Barbara S BeckmanPharmacological Reports : PR|June 7, 2014
Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survivalMatthew M Gestaut, James W Antoon, Matthew E Burow, et al.Oncology Reports|April 4, 2012
Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistanceJames W Antoon, Martin D White, Matthew E Burow, et al.Experimental Biology and Medicine (Maywood, N.J.)|August 4, 2012
Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancerJames W Antoon, Martin D White, Jennifer L Driver, et al.Experimental Biology and Medicine (Maywood, N.J.)|June 24, 2009
Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model systemWilliam D Meacham, James W Antoon, Matthew E Burow, et al.Journal of Medicinal Chemistry|August 22, 2009
Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cellsJames W Antoon, Jiawang Liu, Matthew M Gestaut, et al.Molecular Cancer|November 20, 2010
Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalkLyndsay V Rhodes, James W Antoon, Shannon E Muir, et al.Cancer Letters|February 4, 2017
Oncogenic signaling of MEK5-ERK5Van T Hoang, Thomas J Yan, Jane E Cavanaugh, et al.International Journal of Oncology|September 6, 2007
Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppressionYan Tang, Daniel Y Zhao, Steven Elliott, et al.Cancer Investigation|January 19, 2012
Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectivesCaroline H Walker, Barbara A Drew, James W Antoon, et al.Pageof 20